EMI2 expression as a poor prognostic factor in patients with breast cancer

• Main Authors: Anupama Vadhan, Yen‐Yun Wang, Shyng‐Shiou F. Yuan, Yi‐Chen Lee, Stephen Chu‐Sung Hu, Jyun‐Yuan Huang, Takashi Ishikawa, Ming‐Feng Hou
• Format: Article
• Language: English
• Published: Wiley 2020-08-01
• Series: Kaohsiung Journal of Medical Sciences
• Subjects: breast cancer; EMI2 (FBXO43); metastasis
• Online Access: https://doi.org/10.1002/kjm2.12208
• ISSN: 1607-551X; 2410-8650

Abstract Early mitotic inhibitor 2 (EMI2, gene symbol FBXO43), an APC/C inhibitor regulated by Plx1, is essential for cytostatic factor (CSF) activity. It belongs to subclass FBXO of the F‐box proteins family. The aim of this study is to examine the clinicopathological significance of EMI2 in breast cancer. In this study, immunohistochemistry analysis was used to evaluate EMI2 expression in breast cancer tissues and then the association between EMI2 expression and clinicopathological factors was examined. Correlation of EMI2 with patient survival was analyzed by Kaplan‐Meier survival curves. Among 192 patients analyzed, 105 (54.7%) had high expression of EMI2, and this was significantly associated with shortened disease free survival and overall survival in breast cancer patients. EMI2 expression was significantly associated with tumor grade (P = .006), tumor size (P < .001), and lymph node metastasis (P = .008). However, there was no significant correlation between EMI2 status and other biomarkers including ER, PR and Her2 status. Our results revealed that elevated EMI2 expression is a risk factor (hazard ratio = 3.93) for breast cancer and overexpression of EMI2 in breast cancer predicts higher risk of metastasis and worse survival. Therefore, EMI2 may be a potential therapeutic target for breast cancer.